Kyverna Therapeutics, Inc. (KYTX)
NASDAQ: KYTX · Real-Time Price · USD
2.560
+0.030 (1.19%)
Mar 11, 2025, 4:00 PM EST - Market closed
Kyverna Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
96
Market Cap
110.52M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | 7.03M | 1.37M | 24.20% |
Dec 31, 2021 | 5.66M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionKYTX News
- 8 days ago - Kyverna Therapeutics to Present at the Leerink Partners Global Biopharma Conference - PRNewsWire
- 4 weeks ago - KYTX Deadline: KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Lawsuit - PRNewsWire
- 4 weeks ago - Investors in Kyverna Therapeutics, Inc. Should Contact The Gross Law Firm Before February 7, 2025 to Discuss Your Rights – KYTX - GlobeNewsWire
- 4 weeks ago - INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics - Accesswire
- 5 weeks ago - Final Deadline for the Kyverna Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - KYTX - PRNewsWire
- 6 weeks ago - KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Lawsuit - PRNewsWire
- 7 weeks ago - Kyverna Therapeutics Appoints Naji Gehchan, MD, MBA, as Chief Medical and Development Officer - PRNewsWire
- 2 months ago - Kyverna Therapeutics to Highlight Near-Term Strategic Priorities and Key Milestones at the 43rd Annual J.P. Morgan Healthcare Conference - PRNewsWire